Motives and Side-Effects of Microdosing With Psychedelics Among Users
Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers
The International Journal of Neuropsychopharmacology May 30, 2019 DOI: 10.1093/ijnp/pyz029 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Placebo-controlled Peer reviewed |
|---|---|
| Sample size | 1,116 |
| Population | Psychedelic users with microdosing experience |
| Topics | Psilocybin Microdosing |
| Keywords | Hallucinogen Placebo Pharmacology |
| Citations | 132 |
| Key findings | Performance enhancement was the main motive for microdosing, but the most common reason for stopping was lack of effectiveness. |
Abstract
Abstract Background Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects.
Methods: An online questionnaire was launched on several websites and fora between March and July 2018. Respondents who had consented, were 18 years of age or older, and had experience with microdosing were included in the analyses.
Results: In total, 1116 of the respondents were either currently microdosing (79.5%) or microdosed in the past (20.5%). Lysergic acid diethylamide (10 mcg) and psilocybin (0.5 g) were the most commonly used psychedelics with a microdosing frequency between 2 and 4 times per week. The majority of users, however, were oblivious about the consumed dose. Performance enhancement was the main motive to microdose (37%). The most reported negative effects were of psychological nature and occurred acutely while under the influence.
Conclusion: In line with media reports and anecdotes, the majority of our respondents microdosed to enhance performance. Negative effects occurred mostly acutely after substance consumption. However, the main reason to have stopped microdosing was that it was not effective. Future experimental placebo-controlled studies are needed to test whether performance enhancement can be quantified and to assess potential negative effects after longer term microdosing.
In the evidence
This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.
-
Performance enhancement was the main motive for microdosing, negative effects were mostly acute psychological effects, and the most common reason for stopping was lack of effectiveness.
Synthesized
-
Performance enhancement was the main motive, negative effects were mostly acute psychological effects, and the most common reason for stopping was lack of effectiveness.
Synthesized
Comparable studies
Other cross-sectional and survey studies on psilocybin and microdosing, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Microdosing psychedelics: Motivations, subjective effects and harm reduction People aged 16 years or older who had used psychedelics and could comprehend written... | 2019 | Cross-sectional survey | n = 525 |
| Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities Adults recruited primarily from the online forum Reddit | 2020 | Cross-sectional survey | n = 909 |
| Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention People who reported microdosing lysergic acid diethylamide or psilocybin in the past 12... | 2020 | Cross-sectional survey | n = 6,753 |
| Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults U.S. adults | 2026 | Cross-sectional survey | n = 1,523 |
| Psilocybin microdosing in the United States: Insights from a nationally representative survey US adults | 2026 | Survey study |
Citations in the library
Cited by 107
- Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects Neuropsychopharmacology October 15, 2020
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness. Frontiers in Pharmacology March 25, 2021
- Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials Frontiers in Psychiatry January 21, 2020
- Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing Scientific Reports January 21, 2021
and 102 more in the library
Cites 11
- Psychedelics and the essential importance of context. Journal of Psychopharmacology February 15, 2018
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
- Modern Clinical Research on LSD Neuropsychopharmacology April 27, 2017
- Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting Psychopharmacology October 24, 2018
- The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial Psychopharmacology November 26, 2018
and 6 more in the library